US · SNSE
Sensei Biotherapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Rockville, MD 02210
- Website
- senseibio.com
Price · as of 2024-12-31
$26.96
Market cap 38.48M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $329.80 | ||||
| 2021 | $54.00 | ||||
| 2022 | $29.00 | ||||
| 2023 | $20.20 | ||||
| 2024 | $9.00 |
AI valuation
Our deep-learning model estimates Sensei Biotherapeutics, Inc.'s (SNSE) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $26.96
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SNSE | Sensei Biotherapeutics, I… | $26.96 | 38.48M | — | — | — | — | -7.50 | 5.89 | — | -6.39 | — | 5.89 | 0.00% | — | — | -58.40% | -1014.51% | -50.37% | 0.10 | -351.81 | 7.70 | 7.59 | 0.21 | -164.00% | — | -2294.00% | -10.98% | -4.53 | -795.13% | 0.00% | 0.00% | 0.00% | -5.96 | -7.60 | — | 10.02 |
| BOLT | Bolt Biotherapeutics, Inc… | $4.52 | 8.68M | +449% | -22% | — | — | -5.28 | 5.82 | 43.30 | -4.68 | — | 5.82 | 100.00% | -949.91% | -820.78% | -74.28% | -221.84% | -48.66% | 0.44 | — | 3.20 | 3.06 | -0.27 | -984.00% | -236.00% | -1205.00% | -18.42% | -3.87 | -186.26% | 0.00% | 0.00% | 0.00% | -4.26 | -5.07 | 40.42 | -3.22 |
| CING | Cingulate Inc. | $6.27 | 35.15M | — | — | — | — | -0.95 | 1.97 | — | -0.51 | — | 1.97 | 0.00% | — | — | -5305.02% | 1019.77% | -169.38% | 0.68 | — | 2.55 | 2.46 | 0.48 | -9673.00% | — | 2231.00% | -126.84% | -3.71 | 1216.50% | 0.00% | 0.00% | 71.84% | -0.49 | -0.41 | — | -11.88 |
| CLRB | Cellectar Biosciences, In… | $3.25 | 10.36M | — | — | — | — | -0.26 | 0.82 | — | 0.22 | — | 0.82 | 0.00% | — | — | -17221.69% | 330.97% | -237.45% | 0.03 | — | 2.58 | 2.48 | 0.44 | -6010.00% | — | 4346.00% | -406.92% | -5.07 | 304.82% | 0.00% | 0.00% | 117.61% | 0.21 | 0.23 | — | -18.97 |
| COCP | Cocrystal Pharma, Inc. | $1.05 | 10.76M | — | — | — | — | -0.99 | 1.82 | — | -0.52 | 0.00 | 1.82 | 0.00% | — | — | -97.50% | -1066.39% | -78.29% | 0.19 | — | 4.77 | 4.56 | 0.45 | 9042632.00% | — | 1156.00% | -95.36% | -6.79 | -983.78% | 0.00% | 0.00% | 0.00% | -0.52 | -0.56 | — | -35.62 |
| DWTX | Dogwood Therapeutics, Inc… | $2.85 | 5.45M | — | — | — | — | -0.55 | 0.11 | — | -0.61 | -0.71 | -0.51 | 0.00% | — | — | -36.28% | -37.33% | -25.08% | 0.24 | -132.63 | 5.21 | 4.67 | -0.06 | 7759.00% | — | 8049.00% | -129.59% | -2.77 | -26.84% | 0.00% | 0.00% | 0.01% | -0.62 | -0.86 | — | -1.22 |
| EVGN | Evogene Ltd. | $0.88 | 7.65M | +2,548% | -33% | — | — | -0.47 | -5.81 | 0.99 | -0.39 | — | -0.62 | 39.81% | -255.36% | -193.69% | -340.58% | 381.57% | -39.69% | -8.87 | -175.27 | 1.15 | 0.90 | 0.16 | -4474.00% | 5090.00% | -910.00% | -241.06% | -1.05 | 356.85% | 0.00% | 0.00% | 0.00% | -0.28 | -0.29 | 0.70 | -10.92 |
| IMNN | Imunon, Inc. | $3.25 | 8.19M | — | — | — | — | -0.56 | 2.47 | — | -0.32 | — | 2.47 | 0.00% | — | — | -211.21% | 3263.61% | -117.72% | 0.27 | — | 1.67 | 1.23 | 0.26 | -2500.00% | — | -303.00% | -180.33% | -3.94 | 3221.31% | 0.00% | 0.00% | 4.96% | -0.30 | -0.30 | — | -63.56 |
| MRKR | Marker Therapeutics, Inc. | $1.48 | 15.98M | +3,230% | -2% | — | — | -1.26 | 0.73 | 2.04 | 0.51 | — | 0.73 | -104.33% | -168.69% | -162.82% | -65.81% | 1313.50% | -54.82% | 0.00 | — | 6.36 | 6.22 | 1.73 | -3834.00% | 9906.00% | -3364.00% | -81.00% | -3.15 | 1288.92% | 0.00% | 0.00% | 30.30% | 0.51 | 0.52 | -0.87 | -26.44 |
| TRAW | Traws Pharma, Inc. | $1.65 | 7.87M | +1,216% | +24,103% | — | — | -0.08 | -0.14 | 19.44 | 0.10 | -0.14 | -0.14 | 94.69% | -21835.40% | -24192.04% | 521.75% | 156.37% | -229.51% | 0.00 | — | 2.16 | 2.00 | 0.13 | 5601.00% | 0.00% | 6601.00% | -678.00% | -2.58 | 94.40% | 0.00% | 0.00% | 11.77% | 0.34 | 0.57 | -74.97 | -42.23 |
About Sensei Biotherapeutics, Inc.
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
- CEO
- Christopher W. Gerry
- Employees
- 14
- Beta
- 0.28
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $26.96) − 1 = — (DCF, example).